交互作用检验与多基因风险评分估计精神分裂症治疗抵抗相关常见遗传变异
该研究对精神分裂症治疗抵抗(TRS)与非TRS进行两项全基因组关联研究(GWAS),并在两个独立队列中用多基因风险评分验证。TRS表现为可检测遗传力的多基因性状,并与智力和认知相关性状存在遗传相关;TRS与氯氮平使用史在多基因风险评分分析中呈正相关。
要点
- TRS在GWAS中表现为多基因性状,可检测遗传力为1%至4%。
- TRS与智力和认知相关性状存在遗传相关,遗传相关系数为0.41至0.69。
- CardiffCOGS样本中TRS与氯氮平使用史正相关(r2=2.03%;P=.001),STRATA-G样本重复验证(r2=1.09%;P=.04)。
核心结论
- 常见遗传变异与TRS存在差异性关联,这些关联可能因既往广泛定义精神分裂症的大样本GWAS合并而被掩盖。
- 研究结果提示,meta分析方法可用于研究患者结局包括治疗抵抗。
研究设计与样本
- 两项精神分裂症病例对照GWAS,病例样本定义为TRS个体(n=10 501)和非TRS个体(n=20 325)。
- 基因型数据取自CLOZUK和精神病学基因组学联盟(PGC)精神分裂症研究。
- GWAS阶段共纳入85 490名参与者(48 635名[56.9%]男性),PRS验证阶段共纳入1380名参与者(859名[62.2%]男性)。
- 结果在2个独立精神分裂症队列中用多基因风险评分(PRS)验证:患病率样本817人(CardiffCOGS)和发病率样本563人(STRATA-G)。
主要发现
- TRS表现为多基因性状,可检测遗传力为1%至4%。
- 若干与智力和认知相关的性状与TRS存在遗传相关,遗传相关系数为0.41至0.69。
- CardiffCOGS患病率样本中,TRS与氯氮平使用史呈正相关(r2=2.03%;P=.001)。
- STRATA-G发病率样本重复验证了TRS与氯氮平使用史的正相关(r2=1.09%;P=.04)。
关键数值与推荐
- TRS定义在GWAS和独立验证队列的PRS分析中保持一致。
- GWAS比较TRS与非TRS的等位基因关联效应量差异,以反映治疗抵抗而非精神分裂症本身。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts. OBJECTIVE: To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples. DESIGN, SETTING, AND PARTICIPANTS: Two case-control genome-wide association studies (GWASs) of schizophrenia were performed in which the case samples were defined as individuals with TRS (n = 10 501) and individuals with non-TRS (n = 20 325). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G]). MAIN OUTCOMES AND MEASURES: GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition. RESULTS: The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine (r2 = 2.03%; P = .001), which was replicated in the STRATA-G incidence sample (r2 = 1.09%; P = .04). CONCLUSIONS AND RELEVANCE: In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance.
引用
- Pardiñas AF, Smart SE, Willcocks IR, et al. Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry. 2022. PMID: 35019943. doi:10.1001/jamapsychiatry.2021.3799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。